86. 肺動脈性肺高血圧症 [臨床試験数:1,083,薬物数:667(DrugBank:122),標的遺伝子数:98,標的パスウェイ数:185

Searched query = "Pulmonary arterial hypertension", "PAH", "IPAH", "HPAH", "Eisenmenger syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03344159April 1, 201828/9/2017Spironolactone Therapy in Chronic Stable Right HF TrialSpironolactone Therapy in Chronic Stable Right HF TrialChronic Right-Sided Heart Failure;Pulmonary Arterial Hypertension;Pulmonary Hypertension, Primary, 2;Pulmonary Hypertension, Primary, 3;Pulmonary Hypertension, Primary, 4;Cardiomyopathy Right VentricularDrug: Spironolactone;Drug: Placebo;Radiation: PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82;Diagnostic Test: Cardiac MRI (Gadolinium enhanced)Ottawa Heart Institute Research CorporationNULLSuspended18 YearsN/AAll30Phase 4Canada
2NCT02253394September 201517/9/2014The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension StudyThe Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study (The CAPS-PAH Study)Pulmonary Arterial HypertensionDrug: Ambrisentan plus Spironolactone;Drug: Ambrisentan plus PlaceboBrigham and Women's HospitalGilead SciencesTerminated18 YearsN/AAll2Phase 4United States
3NCT01712620January 10, 201420/10/2012Spironolactone for Pulmonary Arterial HypertensionA Pilot Study of the Effect of Spironolactone Therapy on Exercise Capacity and Endothelial Dysfunction in Pulmonary Arterial HypertensionPulmonary Arterial HypertensionDrug: Spironolactone;Drug: PlaceboNational Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI);National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);University of Pennsylvania;University of Maryland, College Park;Medstar Health Research Institute;New England Medical Center, Tufts University School of MedicineRecruiting18 YearsN/AAll70Phase 2United States
4NCT01468571July 20113/11/2011Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial HypertensionEffects of Spironolactone on Collagen Metabolism in Pulmonary Arterial HypertensionPulmonary HypertensionDrug: Spironolactone;Drug: PlaceboBaylor College of MedicineNational Heart, Lung, and Blood Institute (NHLBI)Recruiting18 YearsN/ABoth50Phase 4United States
5NCT00811486January 200918/12/2008Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular FailureBody Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular FailureRight Heart Failure;Pulmonary HypertensionDrug: Spironolactone and conivaptanUniversity of Colorado, DenverNULLWithdrawn18 Years75 YearsBoth0N/AUnited States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00240656October 200517/10/2005Spironolactone Combined With Captopril and Carvedilol for the Treatment of Pulmonary Arterial HypertensionOfficial Title: Spironolactone Combined With Captopril and Carvedilol for the Treatment of Patients With Pulmonary Arterial Hypertension Associated With Congenital Heart Disease—Focus on Pulmonary Artery RemodelingHypertension, PulmonaryDrug: spironolactone captopril carvedilolHebei Medical UniversityNULLCompletedN/A80 YearsBothPhase 1China